Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Research Staffing issues
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of the study is to develop methods to identify predictors of Malignant Hyperthermia.
The current study will use the combination of electronic medical records and genomic information in samples of persons who have exhibited signs of Malignant Hyperthermia (MH) or have family history or high risk of MH to see if risk factors can be identified. These will be compared with control samples of children who have been exposed to the same agents which could induce MH, yet showed no signs of the disorder.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Malignant Hyperthermia | Samples from persons who have a malignant hyperthermia diagnosis. | ||
| Controls | Children who participated in pharmacogenetic research and had exposure to malignant hyperthermia triggering agents. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Number of clinical manifestations of malignant hyperthermia | Incidence of clinical manifestations of MH will be compared among patients with a history of MH to controls (no diagnosis of MH). | Within data collection period (3 years total). |
| Measure | Description | Time Frame |
|---|---|---|
| number of Genetic indications for malignant hyperthermia | genetic indications for malignant hyperthermia will be compared between control subjects and subjects with a diagnosis of MH | Within data collection period (3 years total). |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Cases are selected from the medical records at Cincinnati Children's Hospital Medical Center who have a current malignant hyperthermia diagnosis. Control cases are selected based on previous participation in pharmacogenetic research and had exposure to agents known to trigger malignant hyperthermic episodes.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| John McAuliffe, MD | Children's Hospital Medical Center, Cincinnati | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Cincinnati Children's Hospital Medical Center | Cincinnati | Ohio | 45229 | United States |
Not provided
| ID | Term |
|---|---|
| D008305 | Malignant Hyperthermia |
| ID | Term |
|---|---|
| D007431 | Intraoperative Complications |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D011183 | Postoperative Complications |
Not provided
Not provided
Not provided
Not provided
Not provided
Samples from other approved projects will be used from both malignant hyperthermia cases and controls.
| D000084462 | Hyperthermia |
| D001832 | Body Temperature Changes |
| D012816 | Signs and Symptoms |